Cytokinetics director sells 5,000 shares at $71.48
Director Lynne B. Parshall sold 5,000 CYTK shares at $71.48, leaving her with 10,784 shares after the 10b5-1 plan transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CYTOKINETICS INC (CYTK) director Lynne B. Parshall reported selling 5,000 shares of common stock on 2026-09-01 in an open market or private transaction at $71.48 per share. After this sale, Parshall holds 10,784 shares of CYTK common stock directly. The filing affirms the transaction was made under a Rule 10b5-1 trading plan.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 5,000 | $71.48 | $357K |
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
Form 4 regulatory
open market or private transaction market
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CYTK director Lynne B. Parshall report?
What are Lynne B. Parshall’s CYTK holdings after the reported sale?
Was the CYTK insider sale made under a Rule 10b5-1 plan?
What is the overall direction of insider activity in this CYTK Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.